Chimeric AAVP Particles for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in achieving controlled and effective delivery of biologically active molecules to tumor cells, with low transfection efficiency and non-specificity, particularly using bacteriophage vectors which lack tropism for mammalian cells.
Innovation Solution
The use of chimeric AAVP particles that can transduce cells with multiple copies of a transgene, combined with a reporter gene system for imaging and monitoring, allowing for site-specific delivery and enhanced expression, and the incorporation of targeting ligands for specific cell binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteriophage vectors are used for gene delivery, then the vectors have no tropism for mammalian cells and are considered poor vehicles for transduction, but they can be adapted to transduce mammalian cells
Solution Approach 1:
The patent merges bacteriophage particles with adeno-associated virus (AAV) elements to create chimeric AAVP vectors. This combination preserves the ease of production and low immunogenicity of bacteriophage while incorporating AAV's ability to transduce mammalian cells efficiently, thereby resolving the contradiction between transduction efficiency and cell type adaptability
Solution Approach 2:
The patent uses targeting ligands as intermediaries to mediate the interaction between bacteriophage vectors and mammalian cell surface receptors. These ligands bridge the gap between the prokaryotic vector and eukaryotic target cells, enabling specific and efficient transduction without requiring the vector to have native tropism for mammalian cells
2Reliability
If ligand-directed targeting is applied to eukaryotic viruses, then transgene delivery is improved, but the native tropism for mammalian cell membrane receptors must be ablated
Solution Approach 1:
The patent extracts the essential transduction capability from AAV and incorporates it into bacteriophage particles, rather than modifying eukaryotic viruses. This extraction approach allows ligand-directed targeting to be implemented on the bacteriophage surface without needing to ablate native tropism, as the bacteriophage lacks such tropism to begin with
Solution Approach 2:
The patent creates a copy of the AAV transduction mechanism within a bacteriophage framework. By copying the essential functional elements needed for mammalian cell transduction and integrating them into the bacteriophage structure, the system achieves targeted gene delivery without the complexity of modifying native viral tropism
3Reliability
If bacteriophage are used to transfer DNA into mammalian cells, then transduction events are rare and reporter gene expression is weak, but transfection methods using calcium phosphate or liposomes enhance efficiency
Solution Approach 1:
The patent enables the bacteriophage vectors to self-target and self-transduce mammalian cells through ligand-receptor interactions. The vectors autonomously navigate to target cells and facilitate their own entry, eliminating the need for complex external transfection procedures like calcium phosphate coprecipitation or liposome-mediated transfection
Data Source
Figure 1A~1B
Figure 1C
Figure 1D
AI summary
Embodiments of the invention are generally directed to compositions and methods of delivering one or more transgene to a target cell, such as a tumor cell, in a site-specific manner to achieve enhanced expression and to constructs and compositions useful in such applications. In certain aspects, expression from a therapeutic nucleic acid may be assessed prior to administration of a treatment or diagnostic procedure to or on a subject.